コンテンツへスキップ
Merck

主要文書

すべての文書を表示

1.03789

スクロース

EMPROVE® EXPERT, Ph. Eur., ChP, JP, NF

別名:

α-D-Glc-(1→2)-β-D-Fru, α-D-グルコピラノシルβ-D-フルクトフラノシド, β-D-フルクトフラノシル-α-D-グルコピラノシド, D(+)-サッカロース, 砂糖

ログインで組織・契約価格をご覧ください。

サイズを選択してください

表示を変更する

この商品について

実験式（ヒル表記法）:
C12H22O11
CAS番号:
57-50-1
分子量:
342.30
UNSPSC Code:
12352201
Beilstein/REAXYS Number:
90825
MDL number:
MFCD00006626
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

Quality Level

500

agency

NF, ChP, JP, Ph. Eur.

product line

EMPROVE® EXPERT

form

solid

feature

RNase and DNase free

impurities

≤0.3 IU/g endotoxin (low)

pH

7 (20 °C, 100 g/L in H2O)

mp

185-187 °C (lit.)

application(s)

liquid formulation
parenterals
pharma/biopharma processes
pharmaceutical

shipped in

ambient

storage temp.

2-30°C

SMILES string

OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O

InChI

1S/C12H22O11/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12/h4-11,13-20H,1-3H2/t4-,5-,6-,7-,8+,9-,10+,11-,12+/m1/s1

InChI key

CZMRCDWAGMRECN-UGDNZRGBSA-N

General description

Chemicals play an important role in the stabilization of a biologic drug during its manufacturing and formulation process – for instance, by preventing aggregation. We offer a wide range of high-quality stabilizers, buffers and salts to successfully purify and formulate your biomolecules. Specifically developed for high-risk applications, they are low in bioburden and endotoxins.
As part of our Emprove® Program, our raw materials are offered with extensive documentation facilitating compliance of your pharma and biopharma product, full supply chain transparency and risk mitigation. Our SAFC® portfolio of high-quality products for biopharmaceutical and pharmaceutical formulation and production withstands strict quality control procedures and is produced according to applicable cGMP guidelines.

Application

Sucrose is used as a stabilizer for the formulation of biomolecules.
We have developed a new filtration-based manufacturing process leading to a sucrose grade with unique quality characteristics: Sucrose Emprove® Expert Ph Eur, ChP, JP, NF is low in endotoxins and has extensively reduced levels of nanoparticulate impurities which can negatively influence the stability of biomolecule formulations, making it the ideal choice for your high-risk applications.

Legal Information

Emprove is a registered trademark of Merck KGaA, Darmstadt, Germany
SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany

Still not finding the right product?

Explore all of our products under スクロース

保管分類

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Emprove®プログラムを使用してGMPを遵守します。

Emprove® Dossiersで資格認定を加速し、コンプライアンスを維持し、時間を節約しましょう。

Dossiers をダウンロード

注意: EmproveSuite.comに移動します。ユーザー名とパスワードはSigmaAldrich.comとは別のもので、異なる場合があります。

無料会員登録すると、数分でEmprove® Dossiersにアクセスできます。 購読プランをアップグレードして、Emprove® Suiteの高度でカスタマイズされたコンテンツをアンロックしてください。

お探しのものが見つかりませんか？Emprove® プログラムのヘルプページをご覧ください。.

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

プロトコル

Low NPI Sucrose for Biopharmaceutical Formulations

This article describes a purification process resulting in low nanoparticulate impurities sucrose, enabling more stable protein formulations.

資料

Use of Stabilizers and Surfactants to Prevent Protein Aggregation

This article outlines critical factors in long-term stability of proteins, and how different stabilizers protect again mechanical and thermal stress.

関連コンテンツ

Formulation

Learn more on mAb subcutaneous or intravenous formulation, and the relevant associated products, including excipients.

Daniel Weinbuch et al.
Pharmaceutical research, 32(7), 2419-2427 (2015-01-30)
In the present study we investigated the root-cause of an interference signal (100-200 nm) of sugar-containing solutions in dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) and its consequences for the analysis of particles in biopharmaceutical drug products. Different
Daniel Weinbuch et al.
Pharmaceutical research, 34(12), 2910-2921 (2017-10-27)
To investigate the effect of nanoparticulate impurities (NPIs) isolated from pharmaceutical-grade sucrose, on the stability of monoclonal antibodies (mAbs). NPIs were purified from pharmaceutical-grade sucrose and spiked into trastuzumab, rituximab, infliximab, and cetuximab formulations. The stability of the mAbs as

グローバルトレードアイテム番号

カタログ番号GTIN
1.03789.902504054839595486
1.03789.100004054839593604
1.03789.901204054839595363